Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 54

1.

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.

Wilson TR, Xiao Y, Spoerke JM, Fridlyand J, Koeppen H, Fuentes E, Huw LY, Abbas I, Gower A, Schleifman EB, Desai R, Fu L, Sumiyoshi T, O'Shaughnessy JA, Hampton GM, Lackner MR.

Breast Cancer Res Treat. 2014 Nov;148(2):315-25. doi: 10.1007/s10549-014-3163-8. Epub 2014 Oct 22.

2.

Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.

Fridlyand J, Simon RM, Walrath JC, Roach N, Buller R, Schenkein DP, Flaherty KT, Allen JD, Sigal EV, Scher HI.

Nat Rev Drug Discov. 2013 Oct;12(10):743-55. doi: 10.1038/nrd4101. Epub 2013 Sep 6.

PMID:
24008432
3.

An industry statistician's perspective on PHC drug development.

Fridlyand J, Yeh RF, Mackey H, Bengtsson T, Delmar P, Spaniolo G, Lieberman G.

Contemp Clin Trials. 2013 Nov;36(2):624-35. doi: 10.1016/j.cct.2013.04.006. Epub 2013 May 3. Review.

PMID:
23648396
4.

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, Haverty PM, Pandita A, Mohan S, Sampath D, Friedman LS, Ross L, Hampton GM, Amler LC, Shames DS, Lackner MR.

Clin Cancer Res. 2012 Dec 15;18(24):6771-83. doi: 10.1158/1078-0432.CCR-12-2347. Epub 2012 Nov 7.

5.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J.

Nature. 2012 Jul 26;487(7408):505-9. doi: 10.1038/nature11249.

6.

Analysis of tumor burden versus progression-free survival for Phase II decision making.

Fridlyand J, Kaiser LD, Fyfe G.

Contemp Clin Trials. 2011 May;32(3):446-52. doi: 10.1016/j.cct.2011.01.010. Epub 2011 Jan 23.

PMID:
21266203
7.

Statistical techniques to construct assays for identifying likely responders to a treatment under evaluation from cell line genomic data.

Huang EP, Fridlyand J, Lewin-Koh N, Yue P, Shi X, Dornan D, Burington B.

BMC Cancer. 2010 Oct 27;10:586. doi: 10.1186/1471-2407-10-586.

8.

Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma.

Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, Zardo G, Nigro J, James CD, Fridlyand J, Reis RM, Costello JF.

Cancer Res. 2010 Jan 15;70(2):453-62. doi: 10.1158/0008-5472.CAN-09-2189. Epub 2010 Jan 12.

9.

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.

Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB.

Cancer Res. 2009 May 15;69(10):4116-24. doi: 10.1158/0008-5472.CAN-08-3441. Epub 2009 May 12.

10.

Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis.

Kwek SS, Roy R, Zhou H, Climent J, Martinez-Climent JA, Fridlyand J, Albertson DG.

Oncogene. 2009 Apr 30;28(17):1892-903. doi: 10.1038/onc.2009.34. Epub 2009 Mar 30.

11.

Improving melanoma classification by integrating genetic and morphologic features.

Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, Bastian BC.

PLoS Med. 2008 Jun 3;5(6):e120. doi: 10.1371/journal.pmed.0050120.

12.

High-resolution genomic and expression analyses of copy number alterations in breast tumors.

Haverty PM, Fridlyand J, Li L, Getz G, Beroukhim R, Lohr S, Wu TD, Cavet G, Zhang Z, Chant J.

Genes Chromosomes Cancer. 2008 Jun;47(6):530-42. doi: 10.1002/gcc.20558.

PMID:
18335499
13.

Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer.

Lee SA, Ho C, Roy R, Kosinski C, Patil MA, Tward AD, Fridlyand J, Chen X.

Hepatology. 2008 Apr;47(4):1200-10. doi: 10.1002/hep.22169.

PMID:
18214995
14.

Protein biomarker identification in the CSF of patients with CNS lymphoma.

Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL.

J Clin Oncol. 2008 Jan 1;26(1):96-105. Epub 2007 Dec 3.

15.

Evaluation of whole genome amplification protocols for array and oligonucleotide CGH.

Hittelman A, Sridharan S, Roy R, Fridlyand J, Loda M, Collins C, Paris PL.

Diagn Mol Pathol. 2007 Dec;16(4):198-206.

PMID:
18043282
16.

Acquired genomic aberrations associated with methotrexate resistance vary with background genomic instability.

Snijders AM, Hermsen MA, Baughman J, Buffart TE, Huey B, Gajduskova P, Roydasgupta R, Tokuyasu T, Meijer GA, Fridlyand J, Albertson DG.

Genes Chromosomes Cancer. 2008 Jan;47(1):71-83.

PMID:
17943968
17.

Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer.

Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, Kalloger SE, Carlson JW, Ginzinger DG, Celniker SE, Mills GB, Huntsman DG, Gray JW.

Clin Cancer Res. 2007 Oct 1;13(19):5745-55.

18.

Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers.

Yau C, Fedele V, Roydasgupta R, Fridlyand J, Hubbard A, Gray JW, Chew K, Dairkee SH, Moore DH, Schittulli F, Tommasi S, Paradiso A, Albertson DG, Benz CC.

Breast Cancer Res. 2007;9(5):R59.

19.

Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.

Tomioka N, Oba S, Ohira M, Misra A, Fridlyand J, Ishii S, Nakamura Y, Isogai E, Hirata T, Yoshida Y, Todo S, Kaneko Y, Albertson DG, Pinkel D, Feuerstein BG, Nakagawara A.

Oncogene. 2008 Jan 17;27(4):441-9. Epub 2007 Jul 16.

PMID:
17637744
20.

FBXW7 and DNA copy number instability.

Byrd KN, Huey B, Roydasgupta R, Fridlyand J, Snijders AM, Albertson DG.

Breast Cancer Res Treat. 2008 May;109(1):47-54. Epub 2007 Jun 23.

PMID:
17588203
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk